News stories about Teva Pharmaceutical Industries (NYSE:TEVA) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.9193992371193 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.32 on Friday, hitting $18.37. The stock had a trading volume of 16,831,161 shares, compared to its average volume of 17,417,406. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. The stock has a market cap of $18,883.41, a PE ratio of -1.13, a PEG ratio of 1.61 and a beta of 0.65. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $34.09.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business’s quarterly revenue was down 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.38 EPS. research analysts forecast that Teva Pharmaceutical Industries will post 2.31 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. Vetr downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price objective for the company. in a research report on Monday. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 1st. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, February 15th. Wells Fargo reissued a “sell” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 13th. Finally, Credit Suisse Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “outperform” rating and raised their target price for the company from $20.00 to $23.00 in a report on Sunday, February 11th. Ten analysts have rated the stock with a sell rating, fourteen have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.81.

In other news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares in the company, valued at approximately $876,094.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 7,636 shares of company stock valued at $149,390 in the last quarter. Company insiders own 7.10% of the company’s stock.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-receiving-somewhat-favorable-press-coverage-report-finds/1937444.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.